NEW YORK — Alexander E. Perl, MD, associate professor in the leukemia program at Abramson Cancer Center at University of Pennsylvania, spoke at HemOnc Today New York about treatment advances for acute myeloid leukemia.
“For decades, AML has been a disease where our therapeutic approach [entailed making] a simple determination if the patient was fit and, if so, we gave them [7+3 with cytarabine and an anthracycline]. If patients were not fit, we gave them low-intensity chemotherapy and supportive care and hoped for the best,” Perl told HemOnc Today. “Patients today still do receive these therapies but, what has been remarkable is how we expanded on them by new drugs that have been integrated into this backbone and really dramatically improved response rate and survival.”
The development of molecularly targeted agents — many of which are active in combination with chemotherapy or by themselves — also have helped increase anti-leukemic responses, Perl said.
Disclosure: Perl reports honoraria from, consultant/advisory board roles with or research funding to his institution from AbbVie, Actinium Pharmaceuticals, Agios, Arog, Astellas, Bayer, BioMed Valley Discoveries, Daiichi Sankyo, FujiFilm, Jazz Pharmaceuticals, Novartis, NewLink Genetics and Takeda.